undamentalytics Newsletter
Sign in

Immunitybio, Inc. cash flow statement

In fiscal 2025, Immunitybio, Inc.'s operations generated −$305m of cash; it spent $3.8m on capital projects, leaving free cash flow of −$309m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−1−5−25−39−49−63−152−172−274−338−367−391−305−281
Depreciation and amortisation00146101413141819181616
Stock-based pay1121174372332574049343734
Capital spending0027351342347831747
Free cash flow−1−6−28−45−84−76−156−173−308−416−397−398−309−288
Free cash flow after stock pay−2−6−239−119−121−100−160−176−365−456−447−433−346−322
Share buybacks—0516150300—————
Shares issued010000308616560————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: IBRX vs NUVBBEAM vs IBRXABUS vs IBRXIBRX vs KPTI

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Immunitybio, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Immunitybio, Inc.